SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is drawing significant attention as the community eagerly anticipates pivotal Phase 3 data for its GPS cancer immunotherapy, with CEO comments on potential curative outcomes driving strong speculation of a massive short squeeze. Investors are actively dismissing bearish takes, instead focusing on shattered technical resistance and accumulation signals that point to a major market revaluation or buyout.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is rallying as market sentiment interprets recent statements on the Mideast conflict as a sign of de-escalation, sparking a 'Trump pump' and optimistic price targets among bulls, while skeptics warn of market manipulation, rising oil prices, and continued geopolitical uncertainty.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is heavily discussed ahead of its earnings report, with investor sentiment torn between the potential of its AI infrastructure and cloud growth, versus significant concerns over its substantial debt load and capital expenditures, particularly after recent developments around its data center partnerships.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to investor concerns over a recently announced convertible senior notes offering, which has sparked questions about potential dilution and management's confidence despite a strong cash position. This comes amidst ongoing community speculation regarding a potential buyout and anticipation for accelerating sales of its gene therapy, Casgevy, and future pipeline updates.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending as its co-founders establish a new mRNA innovations company and Pfizer reportedly sells its stake, fueling community debate over the company's strategic pivot to its robust oncology pipeline, backed by significant cash reserves, amidst broader market skepticism about mRNA technology.

Kohl's Corp. engages in the operation of family-oriented department stores. Its business line includes apparel, footwear, and accessories for women, men, and children, home products, beauty products, and accessories. The stores generally carry a consistent merchandise assortment with some differences attributable to regional preferences. The company was founded in 1962 and is headquartered in Menomonee Falls, WI.

Kohl`s Corp.

Kohl's Corp

Kohl's is a hot topic after its recent earnings showed a beat on Q4 results but presented a cautious outlook for the coming fiscal year, fueling mixed sentiment. While many in the community are debating short squeeze potential and highlighting the company's substantial real estate assets, others are concerned about soft sales trends and the broader challenging retail landscape.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is actively discussed following an analyst upgrade highlighting strong demand for its upcoming R2, which is set for a highly anticipated unveiling on March 12. This event is fueling community excitement and debate over its transformative potential and pricing amidst rising oil costs.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending as its recent earnings and management commentary highlight balance sheet stability, positive free cash flow, and international growth, leading to strong community discussion about its significant undervaluation and AI leadership within the expanding telehealth sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending amidst community discussion surrounding a recent deadline for submitting crucial Full Self-Driving data to NHTSA, which many believe will impact the stock's "autonomy premium" and regulatory outlook. This comes as the company faces a series of executive departures, adding to investor scrutiny of its valuation and market position against intensifying EV competition.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a substantial Q4 earnings beat, driven by strong MIPLYFFA sales, which has sparked widespread community optimism about the company's shift to profitability and its undervalued status, with many anticipating further upside from upcoming European approval.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FY2027 Earnings Estimate for BBIO Issued By HC Wainwright

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - HC Wainwright issued their FY2027 earnings per share estimates for BridgeBio Pharma in a report released on Monday, March 9th. HC Wainwright...

BridgeBio Pharma (NASDAQ:BBIO) Director Sells $4,211,425.27 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 64,921 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at...

Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrea Ellis sold 64,921 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of...

GW&K Investment Management LLC Takes Position in BridgeBio Pharma, Inc. $BBIO

GW&K Investment Management LLC purchased a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) in the 3rd quarter, according to its most recent disclosure with the Securities...

BridgeBio Pharma Talks Atrubie Momentum, Phase 3 Wins as Tafamidis IP Trial Looms

BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar outlined the company's recent clinical progress, commercial momentum, and near-term regulatory plans during a fireside chat at TD Cowen's 46th Annual...

Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO

Aisling Capital Management LP raised its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 0.4% in the third quarter, according to the company in its most recent disclosure...

Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO

Rafferty Asset Management LLC decreased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.8% during the 3rd quarter, according to the company in its most recent...

Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO

Intech Investment Management LLC trimmed its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 22.6% during the 3rd quarter, according to its most recent 13F filing with the...

Okabena Investment Services Inc. Makes New $816,000 Investment in BridgeBio Pharma, Inc. $BBIO

Okabena Investment Services Inc. acquired a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and...

Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO

Monashee Investment Management LLC lessened its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 21.6% during the third quarter, according to the company in its most recent...

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Current Price	$65.64
Prev Close	$65.36
Open	$65.17
Dividend Yield	0.00%
50-Day Moving Average	$73.65
Beta	1.31
Avg. Volume	3.65M
PE Ratio	-17.27

52-Week High	$84.94
52-Week Low	$28.33
Market Capitalization	$13.08B
EPS (Annual)	-$3.79
Price to Book	-6.10
Revenue Per Employee	$598,421.93

BBIO
BridgeBio Pharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BBIO News

BBIOBridgeBio Pharma Inc